1
|
Abstract
Renal carcinoma represents about 3% of all adult tumors, with an estimate of 31,900 new cases diagnosed in 2003 in the United States. In the early phase of its natural history, renal cancer is potentially curable by surgery, but if the disease presents any signs of metastasis, the chances of survival are remote, even though anecdotal cases characterized by long survival have been reported. In fact, the treatment of metastatic renal cancer remains unsatisfactory. Systemic treatment with single agents and with polychemotherapy, with or without cytokine-based immunotherapy, has not been successful, obtaining very low response rates without a significant benefit in overall survival. This review highlights the most interesting issues regarding conventional therapeutic strategies, in localized and in advanced disease. New approaches such as monoclonal antibodies, vaccines, gene therapy, angiogenesis inhibitors and allogeneic cell transplantation and their possible clinical applications are also discussed.
Collapse
Affiliation(s)
- Luca Gattinoni
- Operative Unit of Medical Oncology B, National Cancer Institute, Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Bronte G, Franchina T, Alù M, Sortino G, Celesia C, Passiglia F, Savio G, Laudani A, Russo A, Picone A, Rizzo S, De Tursi M, Gambale E, Bazan V, Natoli C, Blasi L, Adamo V, Russo A. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. Oncotarget 2017; 7:35803-35812. [PMID: 26993607 PMCID: PMC5094963 DOI: 10.18632/oncotarget.8130] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Accepted: 02/28/2016] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Second-line treatment for advanced non-small-cell lung cancer (NSCLC) patients includes monotherapy with a third-generation cytotoxic drug (CT) or a tyrosine kinase inhibitor (TKI). These options are the actual standard for EGFR wild-type (WT) status, as patients with EGFR mutations achieve greater benefit by the use of TKI in first-line treatment. Some clinical trials and meta-analyses investigated the comparison between CT and TKI in second-line, but data are conflicting. METHODS We designed a retrospective trial to gather information about TKI sensitivity in comparison with CT. We selected from clinical records patients treated with at least 1 line of CT and at least 1 line of TKI. We collected data about age, sex, performance status, comorbidity, smoking status, histotype, metastatic sites, EGFR status, treatment schedule, better response and time-to-progression (TTP) for each line of treatment and overall survival (OS). RESULTS 93 patients met selection criteria. Mean age 66,7 (range: 46-84). M/F ratio is 3:1. 39 EGFR-WT and 54 EGFR-UK. All patients received erlotinib or gefitinib as second-line treatment or erlotinib as third-line treatment. No TTP differences were observed for both second-line (HR:0,91; p = 0,6333) and third-line (HR:1.1; p = 0,6951) treatment (TKI vs CT). A trend of a benefit in OS in favor of 3rd-line TKI (HR:0,68; p = 0,11). CONCLUSIONS This study explores the role of TKIs in EGFR non-mutated NSCLC patients. OS analysis highlights a trend to a benefit in patients who received TKI in third-line, even if this result is statistically non-significant. Further analysis are needed to find an explanation for this observation.
Collapse
Affiliation(s)
- Giuseppe Bronte
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Tindara Franchina
- Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy
| | | | - Giovanni Sortino
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Claudia Celesia
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Francesco Passiglia
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | | | - Agata Laudani
- Medical Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy
| | - Alessandro Russo
- Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy
| | - Antonio Picone
- Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy
| | - Sergio Rizzo
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Michele De Tursi
- Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti, Italy
| | - Elisabetta Gambale
- Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti, Italy
| | - Viviana Bazan
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Clara Natoli
- Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti, Italy
| | - Livio Blasi
- Medical Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy
| | - Vincenzo Adamo
- Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy
| | - Antonio Russo
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| |
Collapse
|
3
|
Giordano A, Verba R, Zivieri R, Laudani A, Puliafito V, Gubbiotti G, Tomasello R, Siracusano G, Azzerboni B, Carpentieri M, Slavin A, Finocchio G. Spin-Hall nano-oscillator with oblique magnetization and Dzyaloshinskii-Moriya interaction as generator of skyrmions and nonreciprocal spin-waves. Sci Rep 2016; 6:36020. [PMID: 27786261 PMCID: PMC5081538 DOI: 10.1038/srep36020] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 10/06/2016] [Indexed: 11/18/2022] Open
Abstract
Spin-Hall oscillators (SHO) are promising sources of spin-wave signals for magnonics applications, and can serve as building blocks for magnonic logic in ultralow power computation devices. Thin magnetic layers used as “free” layers in SHO are in contact with heavy metals having large spin-orbital interaction, and, therefore, could be subject to the spin-Hall effect (SHE) and the interfacial Dzyaloshinskii-Moriya interaction (i-DMI), which may lead to the nonreciprocity of the excited spin waves and other unusual effects. Here, we analytically and micromagnetically study magnetization dynamics excited in an SHO with oblique magnetization when the SHE and i-DMI act simultaneously. Our key results are: (i) excitation of nonreciprocal spin-waves propagating perpendicularly to the in-plane projection of the static magnetization; (ii) skyrmions generation by pure spin-current; (iii) excitation of a new spin-wave mode with a spiral spatial profile originating from a gyrotropic rotation of a dynamical skyrmion. These results demonstrate that SHOs can be used as generators of magnetic skyrmions and different types of propagating spin-waves for magnetic data storage and signal processing applications.
Collapse
Affiliation(s)
- A Giordano
- Department of Mathematical and Computer Sciences, Physical Sciences and Earth Sciences, University of Messina, Messina, Italy
| | - R Verba
- Institute of Magnetism, National Academy of Sciences of Ukraine, Kyiv, Ukraine
| | - R Zivieri
- Department of Physics and Earth Sciences and CNISM Unit of Ferrara, University of Ferrara, Ferrara, Italy
| | - A Laudani
- Department of Engineering, University of Roma Tre, Roma, Italy
| | - V Puliafito
- Department of Engineering, University of Messina, Messina, Italy
| | - G Gubbiotti
- Istituto Officina dei Materiali del CNR (CNR-IOM), Sede Secondaria di Perugia, c/o Dipartimento di Fisica e Geologia, University of Perugia, Perugia, Italy
| | - R Tomasello
- Department of Engineering, Polo Scientifico Didattico di Terni, University of Perugia, Terni, Italy
| | - G Siracusano
- Department of Mathematical and Computer Sciences, Physical Sciences and Earth Sciences, University of Messina, Messina, Italy
| | - B Azzerboni
- Department of Engineering, University of Messina, Messina, Italy
| | - M Carpentieri
- Department of Electrical and Information Engineering, Politecnico di Bari, I-70125 Bari, Italy
| | - A Slavin
- Department of Physics, Oakland University, Rochester, MI 48309, USA
| | - G Finocchio
- Department of Mathematical and Computer Sciences, Physical Sciences and Earth Sciences, University of Messina, Messina, Italy
| |
Collapse
|
4
|
Massimiliano A, Bronte G, Spataro F, Bronte E, Leonardi V, Usset A, Laudani A, Arcuri C, Cusimano M, Russo A. Tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw344.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Bronte G, Franchina T, Alù M, Sortino G, Celesia C, Passiglia F, Savio G, Laudani A, Russo A, Picone A, Rizzo S, Blasi L, Adamo V, Russo A. The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e19030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Giuseppe Bronte
- Medical Oncology Unit, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Tindara Franchina
- Medical Oncology Unit-AOOR Papardo-Piemonte, Messina & Departement of Human Pathology University of Messina, Italy, Messina, Italy
| | | | - Giovanni Sortino
- Medical Oncology Unit, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Claudia Celesia
- Medical Oncology Unit, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Francesco Passiglia
- Medical Oncology Unit, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | | | - Agata Laudani
- Medical Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy
| | - Alessandro Russo
- Medical Oncology Unit-AOOR Papardo-Piemonte, Messina & Departement of Human Pathology University of Messina, Italy, Messina, Italy
| | | | - Sergio Rizzo
- Medical Oncology Unit, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Livio Blasi
- UOC Oncologia Medica, ARNAS Civico, Palermo, Italy
| | - Vincenzo Adamo
- Medical Oncology Unit AOOR Papardo-Piemonte, Department of Human Pathology, University of Messina, Messina, Italy
| | - Antonio Russo
- Medical Oncology Unit, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| |
Collapse
|
6
|
Leonardi V, Palmisano V, Pepe A, Usset A, Manuguerra G, Savio G, Laudani A, De Bella MT, Alù M, Calabria C, Carruba G, Agostara B. Docetaxel and Gemcitabine in the Treatment of Metastatic Breast Carcinoma: A Dose Finding Study. Tumori 2009; 95:427-31. [DOI: 10.1177/030089160909500403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background Patients with metastatic breast cancer previously treated with anthracyclines for advanced disease are usually refractory to any further treatment with anthracyclines and have a poor prognosis. Therefore, new drugs or new combinations of drugs are needed. One approach has been to focus on the type of chemotherapy with low toxicity that preserves quality of life during treatment, such as weekly drug administration. Study design We designed a dose-finding study to determine the maximum tolerated dose of gemcitabine plus docetaxel, given on a weekly schedule in metastatic breast cancer previously treated with anthracyclines. Three escalating doses of gemcitabine (900, 1000 and 1100 mg/m2) on days 1 and 8 in combination with a fixed dose of docetaxel, 35 mg/m2 on days 1 and 8 were planned. Dose-limiting toxicity included grade >3 hematologic toxicity, grade >2 stomatitis, asthenia, diarrhea or organ-specific toxicity (except alopecia). Dose escalation was stopped if 1 out of 3 patients at any dose level experienced dose-limiting toxicity. Results Nine patients received a mean of 5.1 (range, 1–9) cycles. Gastrointestinal and leukopenia were the main dose-limiting toxicity. No patient experienced dose-limiting toxicity at dose level 1; at dose level 2, 2 out of 3 patients had dose-limiting toxicity and 3 additional patients treated at dose level 2 confirmed that the maximum tolerated dose had been reached. Conclusions The recommended gemcitabine dose in combination with docetaxel (35 mg/m2 for a phase II study) was established at 900 mg/m2.
Collapse
Affiliation(s)
- Vita Leonardi
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Valentina Palmisano
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Alessio Pepe
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Antonella Usset
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Giovanna Manuguerra
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Giuseppina Savio
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Agata Laudani
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Manuela Tamburo De Bella
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Massimo Alù
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Caterina Calabria
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Giuseppe Carruba
- Experimental Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| | - Biagio Agostara
- Division of Medical Oncology, Oncologic Department, P.O. M. Ascoli, ARNAS, Civico, Palermo, Italy
| |
Collapse
|
7
|
Alu' M, Laudani A, Leonardi V, Palmisano V, Savio G, Pepe A, Arcuri C, Cusimano M, Calabria C, Agostara B. 3546 POSTER (XELOX)Capecitabine plus Oxaliplatin: clinical efficacy and safety in first-line treatment for metastatic gastric cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71049-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Laudani A, Agostara B, Savio G, Leonardi V, Salvagno L, Palmisano V, Usset A. Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13573 Background: Twice-daily oral capecitabine mimics 5-FU infusion and has superior efficacy, improved safety and convenience compared with 5-FU/LV in MCRC and early-stage colon cancer. Preclinical and phase I/II clinical data suggest supra-additive efficacy of X + irinotecan and no significant pharmacokinetic interactions. We evaluated the efficacy and safety of X plus weekly irinotecan (CAPIRI) in 3-week cycles as first-line treatment for MCRC. Methods: Pts with no prior treatment for MCRC received irinotecan 80 mg/m2 i.v. infusion on d1&8 + capecitabine 1000 mg/m2 orally bid d1–14, q3w. Results: Baseline characteristics of the 39 enrolled pts (22 men/17 women) were: median age 59.9 years (range 38–76), ECOG PS 0–1, colon cancer (n=25), rectal cancer (n=14), metastatic sites (liver 74%, pelvis 20%, nodes 23%, lung 18%, peritoneum 10%, primary tumor 20%). Previous treatments were as follows: adjuvant chemotherapy (36%), radiotherapy (5%), neoadjuvant chemotherapy (3%). Pts received a total of 199 cycles (mean 5.1 per pt, range 1–13). All 39 pts were evaluable for safety and 38 for efficacy. The most common treatment-related grade 3/4 adverse events were nausea/vomiting (23% of pts), diarrhea (10%), and leucopenia (5%). The overall response rate was 45%, including 3 complete and 14 partial responses. A further 8 pts (21%) had stable disease. The duration of response in pts with a complete response was >10 months. Conclusions: These early findings indicate that this combination is effective and well tolerated as first-line treatment for MCRC. Replacing 5-FU with capecitabine in XELIRI offers benefits to the pt in terms of efficacy, safety, convenience, reduced discomfort and avoidance of central venous access compared with infusional 5-FU/LV-based regimens (IFL and FOLFIRI). No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Laudani
- M. Ascoli ARNAS Civico, Palermo, Italy; Oncol Med Osp Civile Vittorio Veneto E Conegliano, Vittorio Veneto, Italy
| | - B. Agostara
- M. Ascoli ARNAS Civico, Palermo, Italy; Oncol Med Osp Civile Vittorio Veneto E Conegliano, Vittorio Veneto, Italy
| | - G. Savio
- M. Ascoli ARNAS Civico, Palermo, Italy; Oncol Med Osp Civile Vittorio Veneto E Conegliano, Vittorio Veneto, Italy
| | - V. Leonardi
- M. Ascoli ARNAS Civico, Palermo, Italy; Oncol Med Osp Civile Vittorio Veneto E Conegliano, Vittorio Veneto, Italy
| | - L. Salvagno
- M. Ascoli ARNAS Civico, Palermo, Italy; Oncol Med Osp Civile Vittorio Veneto E Conegliano, Vittorio Veneto, Italy
| | - V. Palmisano
- M. Ascoli ARNAS Civico, Palermo, Italy; Oncol Med Osp Civile Vittorio Veneto E Conegliano, Vittorio Veneto, Italy
| | - A. Usset
- M. Ascoli ARNAS Civico, Palermo, Italy; Oncol Med Osp Civile Vittorio Veneto E Conegliano, Vittorio Veneto, Italy
| |
Collapse
|
9
|
Abstract
OBJECTIVE A phase II study was performed to evaluate efficacy and safety of the combination vinorelbine and docetaxel in patients with metastatic breast cancer previously treated with anthracycline-based regimens. Overall 41 patients were included in the study. METHODS Treatment consisted of vinorelbine 25 mg/m2 and docetaxel 75 mg/m2, both administered on day 1 every 3 weeks for a maximum of 9 cycles. Most patients (92%) were postmenopausal with a median age of 57 years, and median ECOG performance of 1. Sites of disease were viscera in 42% of patients, bones in 30%, soft-tissues in 32%. Sixty-five percent of patients had >2 metastatic sites. Previous treatments included neo-adjuvant chemotherapy in 7.3% of cases, adjuvant chemotherapy in 71%, and front-line chemotherapy for advanced disease in 50% of cases. RESULTS A total of 273 cycles of chemotherapy were delivered (mean 6 cycles/patient). All patients were assessable for toxicity: alopecia was recorded in all patients, grade 2-3 neutropenia in 34% and grade 4 in 9.7%; grade 2-3 nausea/vomiting in 29%, grade 2-3 mucositis in 24.3%. Out of 39 patients evaluable for response, 7 (18%) complete responses and 13 (33%) partial responses have been recorded with an overall response rate of 51%. Six patients (15%) experienced stable disease and 13 patients (33%) progressed. Mean duration of responses was 15.2 months. Median time to progression and median overall survival were 6.2 and 14 months, respectively. CONCLUSION In patients with metastatic breast cancer previously treated with anthracyclines the combination vinorelbine-docetaxel is very active and well tolerated representing a valid therapeutic option for the management of this patient population.
Collapse
Affiliation(s)
- Giuseppina Savio
- Department of Oncology, Division of Medical Oncology, Ospedale M. Ascoli, ARNAS Civico, Palermo, Via Parlavecchio, Palermo, Italy
| | | | | | | | | | | | | |
Collapse
|
10
|
Winograd B, Leonardi V, Palmisano V, Pepe A, Savio G, Laudani A, Blasi L, Alù M, Rondello G, Cusimano MP, Agostara B. Pegylated liposomal doxorubicin (Peg-LD) and paclitaxel in patients with metastatic breast carcinoma: A phase II study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.884] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. Winograd
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - V. Leonardi
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - V. Palmisano
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - A. Pepe
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - G. Savio
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - A. Laudani
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - L. Blasi
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - M. Alù
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - G. Rondello
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - M. P. Cusimano
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| | - B. Agostara
- Schering Plough, Kenilworth, NJ; Medcl Oncology PO “M. Ascoli” ARNAS Civico, Palermo, Italy; Medcl Oncology, Palermo, Italy; Medcl oncology PO, Palermo, Italy
| |
Collapse
|
11
|
Adamo V, Ferraro G, Pergolizzi S, Sergi C, Laudani A, Settineri N, Alafaci E, Scimone A, Spano F, Spitaleri G. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol 2004; 40:525-31. [PMID: 15006626 DOI: 10.1016/j.oraloncology.2003.10.010] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2003] [Accepted: 10/29/2003] [Indexed: 11/24/2022]
Abstract
The purpose of this phase II trial was to investigate the use of paclitaxel and cisplatin in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC), to evaluate tumor response, time to progression, survival, and toxicity of this regimen. Patients with recurrent and/or metastatic HNSCC received 175 mg/mq paclitaxel (PTX) administered as a 3-h intravenous infusion on day 1 and 75 mg/mq cisplatin (CDDP) as a 30(') intravenous infusion on day 2; cycles were repeated every 21 days. From February 1997 to February 2000, 36 patients (18 with locoregionally recurrent disease, 8 with deemed inoperable locally advanced disease, and 8 with metastatic disease) with a median age of 60 years (range 38-73 years) were enrolled. The patients evaluable were 34 for toxic effects, length of survival, and tumor response. The overall response was 41.1%, with two (5.8%) complete responders (CR) and 12 (35.3%) partial responders (PR), 10 (29.4%) patients had stable disease and 10 (29.4%) progressed. The median time to progression (TTP) was 5 months (range 1-49 months), and the median overall survival was 11 months (range 1-53 months). The 1-year-, the 2-year-, and the 3-year-survival rate were 38.2, 17.6 and 14.6, respectively. Up to date of the statistical evaluation four patients were still alive. According to the World Health Organization (WHO) criteria, transient G3 neutropenia and anaemia occurred in seven (20.5%) and four (11.7%) patients, respectively. The predominant non-haematologic toxicities were alopecia and fatigue: Twenty-three (67.6%) patients had G3 alopecia, two patients (5.8%) G3 fatigue and 10 (29.4%) G2, eight (23.5%) G2 myalgia, eight (23.5%) G2 nausea/vomiting, and two (5.8%) G2 mucositis. There were no G4 toxicity and any treatment-related death. Paclitaxel plus cisplatin combination is an active regimen with an acceptable safety profile in recurrent/metastatic HNSCC. This regimen, according to our opinion, is a valid alternative to infusional fluorouracil (5FU)/cisplatin. In fact up to date we can confirm, in taxane era, that paclitaxel, as single agent or in combination, produce response rates similar to cisplatin/5FU regimen, but with more manageable toxicity, especially in the subset of patients with 0-1 ECOG-PS and incurable or locoregional recurrent HNSCC, with short outpatient administration too.
Collapse
Affiliation(s)
- Vincenzo Adamo
- Department of Human Pathology, Azienda Ospedaliera Universitaria, Policlinico "G. Martino" via C. Valeria No. 1, 98125 Messina, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Laudani A, Gebbia V, Leonardi V, Savio G, Borsellino N, Cusimano MP, Calabria C, Stefano R, Agostara B. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. Anticancer Res 2004; 24:1139-42. [PMID: 15154638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
BACKGROUND This study evaluated the antitumor efficacy and safety of a novel oxaliplatin/raltitrexed combination in pretreated advanced colorectal cancer patients. PATIENTS AND METHODS Forty-five patients with 5-fluorouracil-refractory metastatic colorectal cancer received raltitrexed 3.0 mg/m2 as a 15-minute intravenous (i.v.) infusion, followed 45 min later by l-OHP 130 mg/m2 i.v. as 2-h venous infusion on 1 day every 3 weeks. All patients had histologically proven metastatic colorectal cancer, age 18-75, measurable disease and normal baseline biological values. Most patients (60%) had >2 disease sites. All patients were assessed for safety and also for response according to an intent-to-treat fashion. RESULTS The overall response rate was 29% (95% CL 16%-44%) including one CR (2%) and 12 PR (27%). Six patients (16%) showed a stabilization of disease for a tumor growth control rate of 45%. The median time to progression was 4 months (range 1-12+) and median overall survival was 9 months (range 1-29+). CONCLUSION These data confirm that this oxaliplatin/raltitrexed combination is effective against metastatic colorectal carcinoma, well tolerated with low grade toxicity and easy to administer. Further evaluation of this regimen seems warranted as an alternative to fluoropyrimidine-based combinations.
Collapse
Affiliation(s)
- Agata Laudani
- Division of Medical Oncology, Oncological Hospital M. Ascoli, Palermo, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Leonardi V, Savio G, Laudani A, Blasi L, Agostara B. New approaches to breast cancer: oxaliplatin combined with 5-fluorouracil and folinic acid in pretreated advanced breast cancer patients: preliminary reports. Ann N Y Acad Sci 2002; 963:91-7. [PMID: 12095933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Oxaliplatin is a platinum compound that inhibits DNA synthesis. This drug has a broad spectrum of antineoplastic activity, and its results in breast cancer are promising. We began a phase II study in pretreated advanced breast cancer patients using oxaliplatin together with 5-fluorouracil and folinic acid, a combination based on the efficacy of both drugs in breast cancer and their different toxicity profiles. Seventeen patients with advanced breast cancer were treated with oxaliplatin, 5-fluorouracil, and folinic acid, and preliminary data were analyzed. The mean number of courses per patient was 2.82 (range 1-8). The main toxicity was gastrointestinal, with nausea and vomiting G2-3 in 53% of the patients. Hematologic toxicity was moderate with neutropenia G2-3 in 13% of the patients. Among 10 evaluable patients we obtained partial response in one and stabilized the disease in two patients. No data on survival were evaluated. The small number of enrolled and evaluable patients does not permit any conclusions to be drawn. The study is ongoing.
Collapse
Affiliation(s)
- V Leonardi
- Division of Medical Oncology, M. Ascoli Oncologic Hospital - ARNAS Civico, Palermo, Italy.
| | | | | | | | | |
Collapse
|
14
|
Agostara B, Leonardi V, Calabria C, Laudani A, Rondello G. La Terapia Di Supporto Nei Pazienti Con Carcinoma Del Colon-Retto. Tumori 2000; 86:S56-8. [PMID: 10969620 DOI: 10.1177/03008916000863s116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- B Agostara
- Divisione di Oncologia Medica, Ospedale Oncologico M. Ascoli, Palermo
| | | | | | | | | |
Collapse
|
15
|
Adamo V, Maisano R, Laudani A, Altavilla G, Caristi N, D'Angelo A, Ferraro G, Galletti F, Spano F. Phase II study paclitaxel (PTX) and cisplatin (Cis) in advanced and recurrent head&neck cancer. Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81107-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
16
|
Adamo V, Scimone A, Maisano R, Altavilla G, Ferraro G, Laudani A, Pergolizzi S, Zanghì M. Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother 1999; 11:74-7. [PMID: 10078785 DOI: 10.1179/joc.1999.11.1.74] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The role of chemotherapy in metastatic gastric cancer (MGC) is predominantly palliative, therefore regimens with mild toxicity and acceptable activity should be preferred. The combination of etoposide, leucovorin and 5-fluorouracil (ELF) is suitable chemotherapy in this situation. We have enrolled 33 patients with MGC, using the following chemotherapy schedule: l-leucovorin 150 mg/m2 10 minute i.v., followed by etoposide 120 mg/m2 50 minute i.v., followed by 5-fluorouracil 500 mg/m2 10 minute i.v. on days 1-3, every 22 days. All patients are valuable for response, toxicity and survival. Two patients achieved complete response (6%), 10 patients (30%) had a partial response (PR), 9 patients (27%) had stabilization of disease (SD) and 12 patients had disease progression (PD). The median survival for all patients was 6 months (range, 1 to 40+). ELF was well tolerated, the main toxicity being myelosuppression. No toxic deaths occurred. In conclusion, the ELF regimen in our trial demonstrated, in this kind of patient, moderate activity in the absence of relevant toxicity, confirming its suitability in patients in generally poor condition.
Collapse
Affiliation(s)
- V Adamo
- Istituto di Oncologia Università di Messina, Italy
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
We report three cases of autonomously functioning thyroid nodules (AFTNs) that appeared hypofunctioning at radioactive iodine (131I) thyroid scan carried out at initial observation. Since at that time thyroid hormones and thyrotropin (TSH) were also normal, they were initially classified as "cold" nodules and treated with levothyroxine (LT4). The correct diagnosis of AFTN was made years later when a thyroid scintigraphy was repeated. In two of these patients, re-evaluation of the nodule was done because of the development of LT4 intolerance. A possible explanation is that these AFTNs had undergone hemorrhagic/cystic degeneration when they were first studied, but in subsequent years, proliferation of residual AFTN tissue caused the recurrence of a typical functioning nodule.
Collapse
Affiliation(s)
- S Tumino
- Istituto di Medicina Interna e Specialità Internistiche, Cattedra di Endocrinologia, Ospedale Garibaldi, University of Catania, Italy
| | | | | | | | | |
Collapse
|
18
|
Scimone A, Adamo V, Altavilla A, Chillè G, Chiofalo G, Laudani A, Maisano R, Toscano G, Pergolizzi S, Ferraro G. Etoposide, leucovorin and fluorouracil (ELF) in advanced gastric cancer: Our experience. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)86192-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
19
|
Cosentino F, Prato A, Laudani A, Percolla S, Franco S, Veroux PF, Immè A. [Alizapride versus placebo in premedication for esophagogastroduodenoscopy. Double-blind clinical study. Experimental research in vitro]. Minerva Dietol Gastroenterol 1989; 35:35-7. [PMID: 2725928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The pronounced antiemetic properties of Alizapride, one of the new azimidobenzamides suggested the assessment of its efficacy on 40 patients due for oesophagogastroduodenoscopy. The drug proved highly satisfactory as premedication for the examination, significantly inhibiting vomiting and stomach wall tone during the examination as was indicated by in vitro studies.
Collapse
|
20
|
Cosentino F, Valadà F, Bosco R, Giuliano MC, Laudani A, Percolla S, Franco S. [Holter's ECG monitoring in esophagogastroduodenoscopy. Premedication with tiropramide. Preliminary notes]. Minerva Dietol Gastroenterol 1989; 35:31-4. [PMID: 2725927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Endoscopy of the upper digestive tract with flexible instruments is presently a safe, widely used technique in gastrointestinal pathology. Some cases of changes in cardiac rhythm, ventricular fibrillation, ischaemia and cardiac arrest, have, however, been observed during EGDS. The incidence of arrhythmias during EGDS in 41 patients, monitored during the examination with Holter's ECG, has been observed. The results obtained confirm that EGDS does not bring noteworthy cardiovascular changes sufficient to suspend the examination. The absence of parasympathicomimetic effects makes it possible to consider thyropramide one of the drugs of choice in medication before EGDS.
Collapse
|
21
|
Percolla S, Immè A, Laudani A, Franco S, Giuliano MC, Veroux PF, Cosentino F. [Use of the focus duplicator in photographic documentation in digestive fiberendoscopy]. Minerva Dietol Gastroenterol 1988; 34:23-5. [PMID: 3386860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
22
|
Cosentino F, Percolla S, Laudani A, Franco S, Giuliano MC, Immè A, Veroux PF. [Rendu-Osler disease of gastric localization]. Minerva Dietol Gastroenterol 1988; 34:43-6. [PMID: 3386864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
23
|
Caruso F, Donzella MC, Ingegneri R, Laudani A, Sapienza G, Sciuto F. [An aspect of violence: the pathology of movement in the cognitive structure of neurotic and healthy subjects]. Minerva Psichiatr 1986; 27:181-5. [PMID: 3747792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|